Is It Time to Get in on GW Pharmaceuticals While the Price Is Right?
GW Pharmaceuticals (NASDAQ: GWPH) is a crossbreed: a biotech and a cannabis company. Based in England and founded in 1998, the company's focus is examining various cannabinoid formulations as potential therapeutics.
The stock's share price has dropped 53% from a year ago. That's not unusual among cannabis companies; many of them saw a surge in popularity with investors last April, only to come down to earth last summer when investors realized the business models were unsustainable. However, that doesn't appear to be the case for GW Pharmaceuticals, a medical marijuana company with a big upside.
GW Pharmaceuticals's biggest drug is Epidiolex, a liquid, purified form of cannabidiol (CBD). The drug is used for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, two rare forms of epilepsy, in patients older than 2. Last year, in its first full year on the market, the drug brought in $296.4 million, and that number will likely jump this year.
Source Fool.com
